Human chorionic gonadotropin market

Human Chorionic Gonadotropin (HCG) Market, by Product Type (Human Chorionic Gonadotropin and Recombinant Human Chorionic Gonadotropin), by Therapeutic Application (Male Hypogonadism, Female Infertility Treatment, Oligospermic Treatment, Cryptorchidism Treatment, Chronic Pain and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Oct 2022
CMI1011
178 Pages
Excel & Pdf
Pharmaceutical

Summary

The placenta secretes human chorionic gonadotropin hormone (HCG), a hormone, after the implantation of a fertilized zygote in the uterus .HCG plays a major role in stimulating the egg release from the ovary and promotes normal development of the egg. In infertility treatment, the HCG induces ovulation in the women and increases the sperm count in males. A substance called human chorionic gonadotropin (HCG) is produced by trophoblast tissue, which is normally present in early embryos.

Global human chorionic gonadotropin (HCG) market is estimated to be valued at US$ 710.88 Million in 2022 and is expected to exhibit a CAGR of 6.5% during the forecast period (2022-2030).

Figure 1. Global Human Chorionic Gonadotropin Market (HCG) Share (%), by Product Type, 2022

Increasing infertility rates globally are expected to augment growth of the global human chorionic gonadotropin (HCG) market over the forecast period.

Increasing infertility rates globally are expected to augment growth of the global human chorionic gonadotropin (HCG) market over the forecast period. For instance, according to the report published in Galadari Printing and Publishing LLC, 2018, the prevalence of infertility increased with a significant decline in demographics ranging from 6.6 births per woman in the 1970s to 5.22 children in 1980-1985 and 1.73 from 2015- 2020, registering an overall decrease of 160%.

Figure 2. Global Human Chorionic Gonadotropin Market (HCG) Share (%), by Distribution Channel, 2022

Increase in incidence of hypogonadism-related disorders is expected to drive the market growth during the forecast period.

Increase in incidence of hypogonadism-related disorders is expected to drive the market growth during the forecast period. For instance, according to the Endocrine Society (January 2022), globally hypogonadism is a common condition in the male population, with a higher prevalence in older men, obese men, and men with type 2 diabetes.

Human Chorionic Gonadotropin (HCG) Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 710.88 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	6.5%	2030 Value Projection:	US$ 1,176.22 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Human Chorionic Gonadotropin, Recombinant Human Chorionic Gonadotropin By Therapeutics Application: Male Hypogonadism, Female Infertility Treatment, Oligospermic Treatment, Cryptorchidism Treatment, Chronic Pain, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Merck & Co., Inc., Ferring B.V.,Fresenius SE & Co.KGaA,Lupin,Sun Pharmaceutical Industries Ltd,Lee BioSolutions,Serum Institute of India Pvt. Ltd., Scripps Laboratories,Sanzyme Biologics Pvt. Ltd.,VHB Medi Sciences Limited, Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd.
Growth Drivers:	Increasing rate of infertility Increase in incidence of hypogonadism-related disorders
Restraints & Challenges:	Side effects associated with human chorionic gonadotropin (HCG)

Global Human Chorionic Gonadotropin (HCG) Market – Impact of Coronavirus (COVID-19) Pandemic

The lockdown or shutdown has impacted the healthcare industry. The COVID-19 has negatively hampered and disrupted the overall healthcare facilities. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments. while countries such as Saudi Arabia, the U.A.E, Egypt, and others are facing problems with regard to the transportation of raw materials, chemicals, and finished products. The coronavirus or COVID-19 outbreak that started from Wuhan, China has spread across continents, affecting various industries globally .The supply of key materials has been severely disrupted due to forced quarantine and lack of labor. As the link between regional warehouses is not smooth, the transportation of raw material required for development of product between regions cannot be carried out successfully.

Global Human Chorionic Gonadotropin (HCG) Market: Restraint

The major factors that may hinder growth of the global human chorionic gonadotropin (HCG) market include side effects associated with human chorionic gonadotropin (HCG). The side effects associated with human chorionic gonadotropin (HCG) include chest pain, rapid weight gain, trouble in breathing, severe nausea, vomiting, decreased urination, pain or swelling in one leg, or sudden numbness on one side of the body. Furthermore, easy availability of alternatives to treat infertility could act as potential barriers for the market growth.

Key Players

Major players operating in the global human chorionic gonadotropin (HCG) market include Merck & Co., Inc., Ferring B.V.,Fresenius SE & Co.KGaA, Lupin, Sun Pharmaceutical Industries Ltd,Lee BioSolutions,Serum Institute of India Pvt. Ltd., Scripps Laboratories,Sanzyme Biologics Pvt. Ltd.,VHB Medi Sciences Limited Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd.

Table of Content

Table of Contents

*Browse 36 market data tables and 34 figures on "Global Human Chorionic Gonadotropin (HCG) Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global human chorionic gonadotropin (HCG) market during the forecast period (2022-2030)?

Global human chorionic gonadotropin (HCG) market size is estimated to be valued at US$ 710.88 million in 2022 and is expected to exhibit a CAGR of 6.5% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing rate of infertility and increase in incidence of hypogonadism-related disorders are expected to drive the market growth over the forecast period.

Which is the leading therapeutic application segment in the market?

Female Infertility Treatment segment is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factors that may hinder growth of the market include side effects associated with human chorionic gonadotropin (HCG). The side effects associated with human chorionic gonadotropin (HCG) include chest pain, rapid weight gain, trouble in breathing, severe nausea, vomiting, decreased urination, pain or swelling in one leg, or sudden numbness on one side of the body. Furthermore, easy availability of alternatives to treat infertility could act as potential barriers for the market growth.

Which are the major players operating in market?

Major players operating in the market include Merck & Co., Inc., Ferring B.V.,Fresenius SE & Co.KGaA,Lupin,Sun Pharmaceutical Industries Ltd,Lee BioSolutions,Serum Institute of India Pvt. Ltd., Scripps Laboratories,Sanzyme Biologics Pvt. Ltd.,VHB Medi Sciences Limited Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd.